GovernmentUnited Kingdom Official institution
UK extends Casgevy gene-editing treatment to children aged five and over
The UK medicines regulator, the MHRA, has extended its authorisation of Casgevy, a gene-editing treatment, so children aged five and over with severe sickle-cell disease or transfusion-dependent β-thalassemia can receive it. Gene editing changes a person's own DNA to correct the fault behind an illness.
This summary was generated by AI; the official source prevails.
What does it mean?
Children aged five and up with two serious inherited blood conditions can now get a gene-editing treatment called Casgevy in the UK.
What changes?
The source does not state the earlier age limit, so no specific before-and-after comparison can be made beyond the extension to children aged five and over.